These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 10603221)

  • 1. Effectiveness of pneumococcal polysaccharide vaccine for preschool-age children with chronic disease.
    Fiore AE; Levine OS; Elliott JA; Facklam RR; Butler JC
    Emerg Infect Dis; 1999; 5(6):828-31. PubMed ID: 10603221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laboratory surveillance of invasive pneumococcal disease in Australia in 2001 to 2002--implications for vaccine serotype coverage.
    Watson M; Bayley K; Bell JM; Gilbert GL; Hogg G; Keil AD; Krause V; Murphy D; Roche P; Smith HV; Stewart MG; Stylianopoulos J; Turnidge J
    Commun Dis Intell Q Rep; 2003; 27(4):478-87. PubMed ID: 15508501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: implications for development of a conjugate vaccine.
    Butler JC; Breiman RF; Lipman HB; Hofmann J; Facklam RR
    J Infect Dis; 1995 Apr; 171(4):885-9. PubMed ID: 7706815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of pneumococcal conjugate vaccines on burden of invasive pneumococcal disease and serotype distribution of Streptococcus pneumoniae isolates: an overview from Kuwait.
    Mokaddas E; Albert MJ
    Vaccine; 2012 Dec; 30 Suppl 6():G37-40. PubMed ID: 23228356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations.
    Butler JC; Breiman RF; Campbell JF; Lipman HB; Broome CV; Facklam RR
    JAMA; 1993 Oct; 270(15):1826-31. PubMed ID: 8411526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of pneumococcal serotypes and conjugate vaccine formulations.
    Butler JC
    Microb Drug Resist; 1997; 3(2):125-9. PubMed ID: 9185138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine.
    Black S; France EK; Isaacman D; Bracken L; Lewis E; Hansen J; Fireman B; Austrian R; Graepel J; Gray S; Klein NP
    Pediatr Infect Dis J; 2007 Sep; 26(9):771-7. PubMed ID: 17721369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquisition of Streptococcus pneumoniae in South African children vaccinated with 7-valent pneumococcal conjugate vaccine at 6, 14 and 40 weeks of age.
    Nunes MC; Jones SA; Groome MJ; Kuwanda L; Van Niekerk N; von Gottberg A; de Gouveia L; Adrian PV; Madhi SA
    Vaccine; 2015 Jan; 33(5):628-34. PubMed ID: 25541213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.
    Whitney CG; Farley MM; Hadler J; Harrison LH; Bennett NM; Lynfield R; Reingold A; Cieslak PR; Pilishvili T; Jackson D; Facklam RR; Jorgensen JH; Schuchat A;
    N Engl J Med; 2003 May; 348(18):1737-46. PubMed ID: 12724479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae.
    Kyaw MH; Lynfield R; Schaffner W; Craig AS; Hadler J; Reingold A; Thomas AR; Harrison LH; Bennett NM; Farley MM; Facklam RR; Jorgensen JH; Besser J; Zell ER; Schuchat A; Whitney CG;
    N Engl J Med; 2006 Apr; 354(14):1455-63. PubMed ID: 16598044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Streptococcus pneumoniae serogroups 15 and 33: an increasing cause of pneumococcal infections in children in the United States after the introduction of the pneumococcal 7-valent conjugate vaccine.
    Gonzalez BE; Hulten KG; Lamberth L; Kaplan SL; Mason EO;
    Pediatr Infect Dis J; 2006 Apr; 25(4):301-5. PubMed ID: 16567980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members.
    Millar EV; Watt JP; Bronsdon MA; Dallas J; Reid R; Santosham M; O'Brien KL
    Clin Infect Dis; 2008 Oct; 47(8):989-96. PubMed ID: 18781875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regional differences in serotype distribution, pneumococcal vaccine coverage, and antimicrobial resistance of invasive pneumococcal disease among German federal states.
    Imöhl M; Reinert RR; van der Linden M
    Int J Med Microbiol; 2010 Apr; 300(4):237-47. PubMed ID: 19604721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increase in invasive Streptococcus pneumoniae infections in children with sickle cell disease since pneumococcal conjugate vaccine licensure.
    McCavit TL; Quinn CT; Techasaensiri C; Rogers ZR
    J Pediatr; 2011 Mar; 158(3):505-7. PubMed ID: 21193205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine.
    Lexau CA; Lynfield R; Danila R; Pilishvili T; Facklam R; Farley MM; Harrison LH; Schaffner W; Reingold A; Bennett NM; Hadler J; Cieslak PR; Whitney CG;
    JAMA; 2005 Oct; 294(16):2043-51. PubMed ID: 16249418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia.
    Sherwin RL; Gray S; Alexander R; McGovern PC; Graepel J; Pride MW; Purdy J; Paradiso P; File TM
    J Infect Dis; 2013 Dec; 208(11):1813-20. PubMed ID: 24092845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotype distribution and antibiotic resistance of Streptococcus pneumoniae isolated from invasive infections after optional use of the 7-valent conjugate vaccine in Korea, 2006-2010.
    Cho EY; Lee H; Choi EH; Kim YJ; Eun BW; Cho YK; Kim YK; Jo DS; Lee HS; Lee J; Kim MN; Kim DS; Lee HJ
    Diagn Microbiol Infect Dis; 2014 Apr; 78(4):481-6. PubMed ID: 24529940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study.
    Cohen C; von Mollendorf C; de Gouveia L; Lengana S; Meiring S; Quan V; Nguweneza A; Moore DP; Reubenson G; Moshe M; Madhi SA; Eley B; Hallbauer U; Finlayson H; Varughese S; O'Brien KL; Zell ER; Klugman KP; Whitney CG; von Gottberg A;
    Lancet Glob Health; 2017 Mar; 5(3):e359-e369. PubMed ID: 28139443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.